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Abstract 
 
Background and Aims:  We determined the effects of acute and chronic calorie restriction with 
either a low-fat, high-carbohydrate diet or a low-carbohydrate diet on hepatic and skeletal 
muscle insulin sensitivity.  Methods:  Twenty-two obese subjects (body-mass index, 
36.5 0.8kg/m2) were randomized to a high-carbohydrate (>180g/d) or low-carbohydrate 
(<60g/d) energy-deficit diet. A euglycemic–hyperinsulinemic clamp, muscle biopsies, and 
magnetic resonance spectroscopy were used to determine insulin action, cellular insulin signaling 
and intrahepatic triglyceride content before, after 48 h, and after ~11 wks (7% weight loss) of 
diet therapy.  Results: At 48 h, intrahepatic triglyceride content decreased more in the low-
carbohydrate  than the high-carbohydrate diet group (29.6 4.8% vs. 8.9 1.4%; P<0.05), but 
was similar in both groups after 7% weight loss (low-carbohydrate diet, 38.0 4.5% vs. high-
carbohydrate diet, 44.5 13.5%). Basal glucose production rate decreased more in the low-
carbohydrate than the high-carbohydrate diet group at 48 h (23.4 2.2% vs. 7.2 1.4%, P<0.05) 
and after 7% weight loss (20.0 2.4% vs. 7.9 1.2%, P<0.05). Insulin-mediated glucose uptake 
did not change at 48 h, but increased similarly in both groups after 7% weight loss (48.4 14.3%, 
P<0.05).  In both groups, insulin-stimulated phosphorylation of Jun N-terminal kinase decreased 
by 29 13% and phosphorylation of Akt and insulin receptor substrate -1 increased by 35 9% 
and 36 9%, respectively, after 7% weight loss (all p<0.05).  Conclusion: Moderate calorie 
restriction causes temporal changes in liver and skeletal muscle metabolism; 48 h of calorie 
restriction affects the liver (intrahepatic triglyceride content, hepatic insulin sensitivity, and 
glucose production), whereas moderate weight loss affects muscle (insulin-mediated glucose 
uptake and insulin signaling). 
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Insulin resistance is the most common metabolic complication associated with obesity, 2 
and is associated with an increased risk of developing nonalcoholic fatty liver disease (NAFLD) 3 
and type 2 diabetes 1, 2.  A reduced calorie diet is a primary therapy for insulin-resistant obese 4 
persons, because even moderate diet-induced weight loss (5%-10% of body weight) decreases 5 
intrahepatic triglyceride content (IHTG) and improves hepatic and skeletal muscle insulin 6 
sensitivity 3-9.  However, the effect of brief calorie restriction (CR) (≤3d) is confusing because 7 
short-term therapy with a very-low calorie diet (≤800 kcal/d) improves insulin action 10, 11, 8 
whereas short-term fasting induces insulin resistance 12, 13. 9 
The mechanism responsible for the apparent discrepancy between severe and complete 10 
CR on insulin action is not clear, but it is possible that differences in total carbohydrate intake 11 
could be responsible. Data from studies that used the hyperinsulinemic-euglycemic clamp 12 
technique to assess insulin action found that short-term CR with low carbohydrate intake (0-50 13 
g/d) is associated with a decline in hepatic and skeletal muscle insulin sensitivity 14, 15, whereas 14 
short-term CR with adequate carbohydrate intake (100 g/d) is associated with an increase in 15 
both hepatic and skeletal muscle insulin sensitivity 4.  We previously found that carbohydrate 16 
restriction, not total energy restriction, is responsible for initiating the lipolytic response to 17 
fasting; providing daily energy requirements by infusing a lipid emulsion (carbohydrate 18 
restriction) resulted in the same increase in lipolytic rate that occurred after complete fasting 16.  19 
The summation of these data suggest that short-term CR with a low-carbohydrate (LC) diet 20 
could have adverse effects on insulin sensitivity because of increased FFA release into the 21 
circulation, which can cause both hepatic 17, 18 and skeletal muscle 19 insulin resistance. 22 
The current recommended dietary guidelines for treating obesity is to reduce daily 23 
energy intake by 500-1000 kcal 20.  Although, both low-carbohydrate (LC) and high-24 
carbohydrate (HC), low-fat diets are frequently used to lose weight, it is not known whether the 25 
acute and chronic effects of CR on IHTG content and insulin action in liver and muscle differs 26 
between diets. Therefore, the purpose of the present study was to evaluate the acute and 27 
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chronic metabolic effects of a 1000 kcal/d deficit HC ( 180g/d) or LC ( 50g/d) diet in obese 28 
insulin-resistant subjects.  A euglycemic-hyperinsulinemic clamp procedure, in conjunction with 29 
stable isotope tracer infusion, was performed to assess hepatic and muscle insulin sensitivity, 30 
vastas lateralis muscle samples were obtained to determine the concentration of key factors 31 
that regulate skeletal muscle insulin sensitivity, and magnetic resonance spectroscopy was 32 
used to determine IHTG content after short-term CR (48 h) and moderate (7%) weight loss. We 33 
hypothesized that, compared with an energy-deficit HC diet, consuming an energy-deficit LC 34 
diet has adverse effects on insulin action. 35 
 36 
METHODS 37 
 38 
Subjects 39 
 Twenty-two obese subjects (4 men and 18 women; 43.6±2.5 years old, BMI=36.5 0.8 40 
kg/m2) participated in this study.  All subjects completed a medical evaluation, which included a 41 
history and physical examination, standard blood and urine tests, an electrocardiogram, and a 42 
2-h oral glucose-tolerance test (OGTT).  All subjects were considered insulin-resistant, defined 43 
as homeostasis model assessment of insulin resistance (HOMA-IR) value >3.0 21.  In addition, 44 
63% of subjects had impaired glucose tolerance based on a plasma glucose concentration 45 
between 140 and 199 mg/dL at 2 h after a 75 g oral glucose load 22.  Subjects who had diabetes, 46 
a history of excessive alcohol consumption, liver disease, or evidence of other serious illnesses 47 
or organ dysfunction, and subjects who smoked tobacco products or took medications that are 48 
known to alter glucose metabolism were excluded from the study.  All subjects were weight 49 
stable (≤2% change in body weight) and had been sedentary (<1 h of exercise per week) for at 50 
least 3 months before being enrolled in the study. 51 
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The study was approved by the Human Studies Committee of Washington University 52 
School of Medicine in St. Louis, MO.  Written informed consent was obtained from each subject 53 
before their participation in this study. 54 
Experimental Design 55 
 56 
Body Composition Assessments 57 
 Total body fat mass (FM) and fat-free mass (FFM) were determined by using dual-58 
energy x-ray absorptiometry (DXA, Hologic QDR 4500, Waltham, MA) 23.  Total abdominal, 59 
subcutaneous abdominal, and intra-abdominal fat volumes were quantified by using magnetic 60 
resonance imaging (MRI, Siemens Vision 1.5 Tesla imager).  Intrahepatic triglyceride (IHTG) 61 
content was determined by using proton magnetic resonance spectroscopy (MRS) with a 1.5T 62 
scanner (Magneton Vision Scanner; Siemens, Erlanger, Germany) 24; three 2 x 2 x 2 voxels were 63 
analyzed for each subject and the values were averaged for data analyses.  These body 64 
composition assessments were made at baseline (before diet intervention), after 48 h of CR with 65 
either a HC or LC diet, and after subjects lost 7% of their initial body weight and were weight 66 
stable for 4 weeks.   67 
 68 
Euglycemic-hyperinsulinemic clamp procedure 69 
 Subjects were admitted to the inpatient unit of the General Clinical Research Center 70 
(GCRC) on two separate occasions.  A euglycemic-hyperinsulinemic clamp procedure, in 71 
conjunction with stable isotopically labeled tracer infusion, was performed at baseline (before 72 
diet intervention), after 48 h of CR with either a HC or LC diet, and after subjects lost 7% of their 73 
initial body weight and were weight stable for 4 weeks.  Subjects were instructed to abstain from 74 
exercise and to maintain their regular diet for at least 3 days and to abstain from caffeine and 75 
alcohol for at least 24 h before each admission.  Female subjects were studied during the 76 
follicular phase of their menstrual cycle.   77 
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During the first GCRC admission subjects were admitted for 4 days.  In the evening on 78 
the day of admission, subjects consumed a standard meal, containing 15 kcal/kg FFM and 55% 79 
of total energy as carbohydrates, 30% as fat, and 15% as protein at ~1800 h and then fasted 80 
(except for water) and rested in bed until completion of the clamp procedure the next day.  The 81 
following morning, at 0600 h, a catheter was inserted into an antecubital vein of one arm to 82 
infuse stable isotopically labeled glucose, insulin and dextrose; another catheter was inserted in 83 
a contralateral hand vein, which was placed in a thermostatically controlled (65°C) box to obtain 84 
arterialized blood 25.  At 0630 h, resting energy expenditure was determined by using a 85 
metabolic measuring cart (Delta Trac; SensorMedics, Yorba Linda, CA).  At ~0700 h, after a 86 
blood sample was obtained to determine the background glucose enrichment, a primed, 87 
continuous infusion of [6,6-2H2]glucose was started and maintained for 7 h.  At 210 min after 88 
starting the tracer infusion, insulin was infused at a rate of 40 mU·m2 body surface area (BSA)-89 
1·min-1 for 210 min (initiated with a two-step priming dose of 160 mU·m2 BSA-1·min-1 for 5 min 90 
followed by 80 mU·m2 BSA-1·min-1 for 5 min).  Dextrose (20%), enriched with [6,6-2H2]glucose to 91 
~2.5% to minimize changes in plasma glucose enrichment 26, was infused at a variable rate to 92 
maintain euglycemia (plasma glucose concentration of 5.6 mM).  The infusion rate of [6,6-93 
2H2]glucose was decreased by 75% during the clamp procedure to account for the expected 94 
decline in hepatic glucose production.  Blood samples were taken every 10 min during the last 95 
30 min of the basal period and the clamp procedure to determine plasma glucose TTR and 96 
concentration and plasma insulin concentration during basal conditions and insulin infusion. A 97 
muscle biopsy from the vastus lateralis was taken at 240 min (i.e., 30 min after starting the 98 
insulin infusion) to assess specific cellular factors involved in insulin sensitivity.  The tissue was 99 
immediately frozen in liquid nitrogen and then stored at -80°C until final analyses. 100 
 101 
 102 
 103 
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Diet intervention 104 
 After completing the first insulin clamp procedure, subjects were randomized to 105 
treatment with either a low-calorie HC diet or an LC diet. The energy content of the HC and LC 106 
diets were designed to provide a 1000 kcal daily energy deficit, based on an estimated daily 107 
energy requirement (calculated as 1.3 times measured resting energy expenditure); the average 108 
total daily energy intake was ~1100 kcal.  The HC diet provided 180 g carbohydrates (CHO) 109 
per day and ~65% of total daily energy intake as CHO, 20% as fat, and 15% as protein; the LC 110 
diet provided 60 g CHO per day and ~10% of daily energy intake as CHO, 75% as fat, and 111 
15% as protein.   112 
Subjects remained in the GCRC until the second insulin clamp procedure and body 113 
composition assessment were completed.  All food was provided by the GCRC metabolic 114 
kitchen and subjects’ food intake was monitored.  On the first day of the diet intervention (i.e., 115 
the day of the first clamp procedure), the calorie and CHO contents of the diet were adjusted to 116 
account for the glucose calories infused during the clamp procedure.  On the third morning in 117 
the GCRC, the insulin clamp procedure was repeated after 48 h of consuming either a low-118 
calorie HC or low-calorie LC diet.  After completing the second insulin clamp procedure, the 119 
calorie and CHO contents of the diet were again adjusted to account for the glucose calories 120 
infused during the clamp procedure.  The following morning (day 4 in the GCRC), IHTG content 121 
and body composition were evaluated and subjects were then discharged from the GCRC. 122 
 All subjects received detailed dietary instructions by a registered dietician and were 123 
instructed to follow the HC and LC diet until they lost 7% of their total body weight. Subjects 124 
received weekly individual or group behavior therapy and diet education with a registered 125 
dietician and experienced behavior counselor to enhance dietary compliance. Once subjects 126 
achieved a 7% body weight loss (on average after 6±1 wks), total calorie intake was adjusted to 127 
maintain a constant body weight and prevent further weight loss.  After being weight stable at 128 
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their new body weight for at least 4 weeks, subjects were readmitted to the GCRC and the 129 
insulin clamp procedure and body composition analyses were repeated. 130 
 131 
Sample Analyses 132 
  Plasma substrate and hormone concentrations.  Plasma glucose concentration was 133 
determined by using an automated glucose analyzer (YSI 2300 STAT Plus, Yellow Spring 134 
Instrument Co., Yellow Springs, OH).  Plasma insulin and leptin concentrations were measured 135 
by using radioimmunoassay and  enzyme-linked immunosorbent assay kits were used to 136 
measure plasma adiponectin concentrations (Linco Research, St Louis, MO).  The relative 137 
changes in plasma 3-hydroxybutyrate concentrations at 48 h and ~11 wks of CR compared with 138 
baseline values were determined by using a gas chromatography-mass spectrometry platform, 139 
as described previously 27  140 
Plasma glucose isotopic enrichment. Plasma glucose tracer to tracee ratio (TTR) was 141 
determined by using gas chromatography-mass spectrometry (Agilent Technologies/HP 6890 142 
Series GC System – 5973 Mass Selective Detector, Hewlett-Packard, Palo Alto, CA), after 143 
preparing the heptafluorobutyryl derivative of glucose and selectively monitoring ions at m/z 519 144 
and 521 28. 145 
Muscle Akt/PKB, IRS-1, and JNK 1 phosphorylation were determined by using Western 146 
blotting analyses (Muscle Akt/PKB, and JNK 1 phosphorylation) and immunoprecipitation (IRS-1 147 
phosphorylation).  Muscle samples were homogenized in lysis buffer (50 mM Tris, 150 mM 148 
NaCl, and 1% NP40), containing a cocktail of protease and phosphatase (NaF and NaVO4) 149 
inhibitors 29.   Protein content was quantified and then 60 µg protein was electrophoresed by 150 
SDS-PAGE and transferred to nitrocellulose membranes.  Blots were probed with polyclonal 151 
antibodies directed against total Akt/protein kinase B (PKB) (Amersham Biosciences, 152 
Pittsburgh, PA), Akt/ PKB phosphorylated at serine 473 (Amersham Biosciences, Pittsburgh, 153 
PA), total c-Jun N-terminal kinase (JNK; EMD Biosciences, San Diego, CA), and JNK 154 
  9 
phosphorylated at threonine 183 (EMD Biosciences, San Diego, CA).  To evaluate IRS-1 155 
tyrosine phosphorylation, IRS-1 was immunoprecipitated from 500 µg of protein using a 156 
polyclonal antibody against IRS-1 (gift of Mike Mueckler) prior to SDS-PAGE and 157 
immunoblotting with an antibody directed against phosphotyrosine (Cell Signaling, Danvers, 158 
MA) or IRS-1 (gift of Mike Mueckler).  The intensity of bands obtained by Western blotting 159 
analyses was quantified by digitizing the autoradiographic images and using Image Processing 160 
and Analysis in Java Program (ImageJ, National Institutes of Health, Version 1.36b).  The 161 
intensity of the phosphorylated forms of the proteins were corrected for total content of that 162 
protein and normalized to the baseline value (i.e., before intervention); therefore, values are 163 
expressed as percentage change from baseline.   164 
 165 
Calculations 166 
Total (endogenous and exogenous) glucose rate of appearance (Ra) in plasma during 167 
basal conditions and the clamp procedure were calculated by dividing the glucose tracer 168 
infusion rate by the average plasma glucose TTR between 180 and 210 minutes (basal) and 169 
390 and 420 min (clamp) 30.  Basal, endogenous glucose Ra was calculated by subtracting the 170 
glucose tracer infusion rate from total glucose Ra.  It was assumed that glucose Rd was equal 171 
to total glucose Ra.   172 
The homeostasis model assessment of insulin resistance (HOMA-IR) was determined by 173 
dividing the product of plasma glucose concentration (in mM) and plasma insulin concentration 174 
(in mU/L) by 22.5 21.  Hepatic insulin sensitivity index was assessed as the reciprocal of the 175 
Hepatic Insulin Resistance Index, which is calculated as the product of the basal hepatic 176 
glucose production rate (in mol·kg FFM-1·min-1) and fasting plasma insulin concentration (in 177 
mU/L) 31, 32.   Skeletal muscle insulin sensitivity was determined by evaluating the ability of 178 
insulin to stimulate skeletal muscle glucose uptake, assessed as the relative increase in whole-179 
body glucose Rd during insulin infusion compared with baseline values. 180 
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 181 
Statistical Analysis 182 
A two-way analysis of variance with repeated measures was used to compare between 183 
and within group differences in the changes in outcome measures from baseline to 48 hours 184 
and from baseline to 7% weight loss.  Tukey's post-hoc procedure was used to locate 185 
differences, if a significant main effect was found. The relationship between the percent change 186 
in intra-abdominal fat volume and the percent change in IHTG content and HISI were assessed 187 
by using linear regression analysis.   A P-value of ≤0.05 was considered statistically significant.  188 
Data are expressed as means  SEM.  All data were analyzed using SAS (8.2, Cary, NC). 189 
 190 
RESULTS 191 
 192 
Study subject characteristics  193 
Baseline metabolic variables and body composition measurements were not different 194 
between subjects randomized to the HC and LC diet groups (Table 1).  Fifty percent of subjects 195 
in the HC diet group and 58% of subjects in the LC diet group had nonalcoholic fatty liver 196 
disease, defined as IHTG content >5.6% 33.    197 
 198 
Dietary compliance 199 
 Changes in plasma 3-hydroxybutyrate concentrations during CR suggest that study 200 
subjects in both the HC and LC diet groups were compliant with their dietary assignment.  In 201 
subjects randomized to CR with an HC diet, plasma β-hydroxybutyrate increased ~2-fold at 48 h 202 
of CR (P=0.02) and returned to baseline values at 11 wks of CR.  In subjects randomized to CR 203 
with a LC diet, plasma 3-hydroxybutyrate increased ~10-fold at 48 h of CR (P<0.0001) and 204 
remained 10-fold greater than baseline at 11 wks of CR (P=0.002). 205 
 206 
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Body weight and body composition  207 
Short-term CR caused a similar decrease in body weight at 48 h with either diet (Table 208 
2) (mean weight loss for both groups combined=2.0 0.2%, P<0.0001).  Long-term weight loss 209 
after completing the diet intervention was also similar in both groups (Table 2) (mean weight 210 
loss for both groups combined at ~11 wks of dieting=7.5%  0.4% P<0.0001). The time to 211 
achieve 7% weight loss was not different between the AC diet group (6.2±1.0 wks) and the LC 212 
diet group (5.9±1.0 weeks).   213 
Changes in body FM and FFM at ~11 wks of dieting and 7% weight loss were not 214 
different between the HC and LC groups (the average decreases in FM, FFM, and intra-215 
abdominal fat volume in all subjects were 11.3  0.9%, 3.8  0.6%, and 12.0  2.8%, 216 
respectively; all P<0.001) (Figure 1).  Calorie restriction with either the HC or LC diet caused a 217 
progressive decrease in IHTG content.  The relative decrease in IHTG was ~3 times greater in 218 
the LC group than in the HC group at 48 h of CR, but was not different between groups after 219 
~11 wks of CR (~7% weight loss) (Figure 1).  There was not a significant relationship between 220 
percent change in intra-abdominal fat volume and the percent change in IHTG (R2=0.001, 221 
P>0.05). 222 
 223 
Plasma adipokine and hepatic enzymes concentrations. 224 
Plasma leptin concentration decreased similarly in both groups after 48 h (10.8±3.6%) 225 
decrease from baseline in combined groups, P<0.01) and ~11 wks (19.4±6.8%) decrease from 226 
baseline in combined groups, P<0.01) of CR.   Plasma adiponectin concentrations decreased in 227 
both groups after 48 h (8.8±3.5% decrease from baseline in combined groups, P<0.05) and 228 
tended to increase after ~11 wks (12.1±7.2% increase from baseline in combined groups, 229 
P>0.05) of CR.  230 
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Plasma ALT and AST concentrations did not change after 48 h and ~11 wks of CR in 231 
either the HC or LC diet groups.  In the combined groups, plasma ALT concentrations were 29.2 232 
 2.4, 31.1  3.4  and 33.4  5.2 IU/L and plasma AST concentrations were 25.5  2.0, 28.0  233 
2.9, and 26.2  2.8 IU/L at baseline, 48 h and 11 wks of CR, respectively.  234 
 235 
In vivo measures of insulin sensitivity and glucose homeostasis 236 
Plasma glucose, c-peptide, and insulin concentrations. Calorie restriction caused a 237 
decline in plasma glucose, c-peptide and insulin concentrations both after 48 h and ~11 wks 238 
(~7% weight loss) of dieting in the HC and LC groups (Table 2).  There was a trend toward a 239 
greater decrease in both plasma glucose, c-peptide and insulin concentrations in the LC group 240 
than the HC group after both short-term and long-term dieting.  However, only the decrease in 241 
plasma glucose concentration after 48 h of CR and the decrease in plasma insulin concentration 242 
after 7% weight loss were significantly different between groups.   243 
Homeostasis model assessment of insulin resistance.  HOMA-IR improved in both 244 
groups after 48 h of CR and did not change further after ~11 wks of dieting (~7% weight loss) 245 
(Table 2).  However, the decrease in HOMA-IR was greater in the LC than the AC diet group 246 
both after 48 h of CR and 7% weight loss (Table 2). 247 
Hepatic Insulin Sensitivity Index. Hepatic insulin sensitivity increased after 48 h of CR in 248 
both the AC and LC groups, but did not improve further after 11 wks of CR (7% weight loss) 249 
(Figure 3, top panel).  However, the improvement in hepatic insulin sensitivity was greater in the 250 
LC than the AC group, after both 48 h CR and 7% weight loss (Figure 3A). There was not a 251 
significant correlation between percent changes in IHTG content and HISI value (R2=0.083, 252 
P>0.05). 253 
Basal glucose kinetics. Basal glucose Ra decreased after 48 h of CR in both the AC and 254 
LC groups, but was not different between groups and did not change further with more 255 
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prolonged CR and 7% weight loss. Glucose Ra in the combined groups were 13.8  0.4, 256 
12.0 0.4, and  12.2  0.3 µmol/kg FFM/min at baseline, and at 48 h and 11 wks of CR, 257 
respectively (p<0.001 for each CR value compared with baseline value).  The decline in basal 258 
glucose Ra was greater in the LC than the AC group after both short-term (48 h) and long-term 259 
(~11 wks, 7% weight loss) CR (Figure 2). 260 
Insulin-mediated glucose uptake. Plasma insulin concentrations during the clamp 261 
procedure were not different between the HC and LC groups at any time point during the study.  262 
However, plasma insulin concentrations after 48 h (84.3 3.4 µU/mL) and 11 wks 263 
(84.5  .2µU/mL) of CR were ~10% lower than values at baseline (95.4 3.3µU/mL; p<0.0001).  264 
Glucose Rd values during insulin infusion was similar in both groups: 30.0  2.6, 25.0  1.4, and 265 
31.1  2.5 µmol/kg FFM/min at baseline, and at 48 h and 11 wks of CR for the combined groups, 266 
respectively.  The relative increase in glucose Rd during insulin infusion was not greater at 48 h 267 
of CR than at baseline before CR in either diet group.  However, the relative increase in glucose 268 
Rd during insulin infusion was greater after 7% weight loss than at baseline in both diet groups.  269 
Both short-term (48 h) and long-term (11 wks, 7% weight loss) CR caused similar changes in 270 
insulin-mediated increases in glucose Rd in the AC and LC groups, so the data from both 271 
groups are combined (Figure 3, bottom panel). 272 
 273 
Cellular insulin signaling in skeletal muscle 274 
At 48 h of CR, skeletal muscle phosphorylation of Tyr183 JNK, Tyr IRS1, and Ser473 275 
Akt/PKB content assessed after insulin stimulation (30 min of insulin infusion) was not 276 
significantly different than baseline (before CR) in either diet group (Figure 4).  However, at 11 277 
weeks of CR (7% weight loss), insulin-stimulated skeletal muscle phosphoTyr IRS1, and 278 
phosphoSer473 Akt/PKB content increased, whereas phosphoTyr183 JNK content decreased, 279 
compared with baseline in both diet groups. Changes in phosphorylation status of Tyr183 JNK, 280 
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Tyr IRS1, and Ser473 Akt/PKB were similar in the HC and LC groups, so the data from both 281 
groups are combined in Figure 4.  282 
 283 
DISCUSSION 284 
An energy-deficit diet is the cornerstone of therapy for obesity. However, the most 285 
appropriate macronutrient composition of diet therapy needed to improve metabolic health 286 
remains controversial. In the present study, we carefully evaluated the longitudinal metabolic 287 
effects of short-term (48 h; 2% weight loss) and longer-term (11 wks; 7% weight loss) calorie 288 
restriction (1000 kcal/d energy deficit) with either a high- or low- carbohydrate diet in obese, 289 
insulin-resistant but non-diabetic adults.  Our data demonstrate that short-term CR caused a 290 
rapid decrease in IHTG content, increase in hepatic insulin sensitivity, and decrease in 291 
endogenous glucose production rate, whereas longer-term CR and moderate 7% weight loss 292 
improved skeletal muscle insulin sensitivity, in conjunction with an increase in cellular insulin 293 
signaling. In addition, short-term CR with a low-carbohydrate diet caused a greater change in 294 
liver fat content and metabolic function than short-term CR with a high-carbohydrate diet. These 295 
data underscore the complexity of the metabolic effects of CR with diets that differ in 296 
macronutrient composition, and demonstrate temporal differences among organ systems in the 297 
adaptive response to CR itself and subsequent weight loss.  298 
 Our results refute our original hypothesis that a LC diet will cause insulin resistance 299 
because of increased adipose tissue lipolytic rates and excessive FFA release into the 300 
bloodstream. In fact, we found that LC intake rapidly caused a greater reduction in IHTG content, 301 
improvement in hepatic insulin sensitivity, and decrease in endogenous glucose production rate 302 
than consumption of an isocaloric low-fat diet.  The mechanism responsible for the early 303 
beneficial effects on liver metabolism is not known, but is probably related to the greater 304 
decrease in plasma insulin concentrations in subjects consuming the low-carbohydrate diet.  305 
The decline in circulating insulin likely decreased IHTG because of enhanced lipolysis of IHTG 306 
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and hepatic fatty acid oxidation14, and decreased hepatic glucose production because of hepatic 307 
glycogen depletion 17and decreased glycogenolysis 4, 34.  These metabolic alterations are similar 308 
to the physiologic adaptations that occur during the early response to starvation, which are also 309 
triggered by a reduction in carbohydrate intake 16.  However, in contrast with data obtained from 310 
studies evaluating the metabolic effects of brief fasting 12-14, we did not detect a significant 311 
decline in skeletal muscle insulin sensitivity after 48 h of CR with a low-carbohydrate diet.  312 
 Weight loss, but not short-term CR, was necessary to increase skeletal muscle insulin-313 
mediated glucose disposal.  The improvement in muscle insulin sensitivity we observed in vivo 314 
is explained by enhanced cellular insulin signaling (increased insulin stimulated IRS-1 tyrosine 315 
and Akt/PKB serine phosphorylation) detected after 7% weight loss but not after 48 h of CR.  316 
These results are consistent with data from a study conducted in subjects with type 2 diabetes 317 
that found insulin-stimulated Akt/PKB did not change after 2 days of CR 35.  In addition, our data 318 
suggest that the mechanism responsible for the increase in insulin signaling involves down-319 
regulation of JNK, which inhibits IRS-1 serine phosphorylation and the proximal component of 320 
the insulin signaling cascade 36.   Therefore, these findings demonstrate that the increase in 321 
JNK associated with obesity and type 2 diabetes is responsive to nutritional manipulation and 322 
can be normalized by weight loss.    323 
Nonalcoholic fatty liver disease is associated with insulin resistance 37, 38 and is an 324 
important risk factor for diabetes 39. We previously found a linear inverse correlation between 325 
IHTG content and insulin sensitivity in both liver and skeletal muscle 38.  In the present study, 326 
dietary manipulation of IHTG content allowed us to dissociate the interrelationships among 327 
IHTG and insulin sensitivity in liver and skeletal muscle.  After 48 h of CR, IHTG content 328 
decreased by ~20%, which was associated with a decrease in basal glucose production rate 329 
and an increase in hepatic insulin sensitivity, whereas skeletal muscle insulin sensitivity did not 330 
change.  Continued CR until subjects lost 7% of initial body weight caused a further decrease in 331 
IHTG content, without a further decrease in basal glucose production or improvement in hepatic 332 
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insulin sensitivity.  However, 7% weight loss up-regulated skeletal muscle insulin signaling and 333 
increased muscle insulin sensitivity.  These data support the notion of a causal link between 334 
steatosis and hepatic insulin resistance.  The mechanism responsible for the link between IHTG 335 
content and hepatic insulin sensitivity is unknown, but could be related to an accumulation of 336 
intracellular fatty acid metabolites, which can antagonize the effects of insulin signaling on 337 
endogenous glucose production40 338 
Our data provide new insights into the potential mechanism responsible for the marked 339 
improvement in glycemic control observed within days after Roux-en-y gastric bypass (RYGP) 340 
surgery in obese patients with type 2 diabetes 41.  For example, in one study, 90% of patients 341 
were able to discontinue all diabetes medications and maintain normal glycemia at discharge 342 
from the hospital 6 days after RYGP surgery, before much weight loss occurred 42. These 343 
observations have led to the hypothesis that diversion of ingested nutrients from the upper 344 
gastrointestinal tract has beneficial effects on glucose homeostasis, possibly because of an 345 
altered incretin response to meals 43.  However, our results suggest that the rapid decrease in 346 
liver fat and improvement in hepatic insulin sensitivity that occur after brief CR can completely 347 
explain the early improvement in glucose homeostasis observed after bariatric surgery.  Food 348 
intake is limited after RYGP surgery, and patients usually consume less than 250 kcal/d for 349 
several days after the operation 41.  Therefore, the marked postoperative reduction in calorie 350 
intake, itself, likely has profound effects on hepatic fat content and metabolism40.  Moreover, the 351 
decrease in calorie intake makes it is unlikely that diversion of ingested nutrients from the upper 352 
gastrointestinal tract has an important effect on glucose metabolism.  353 
In summary, the data from this study demonstrate that the effect of moderate calorie 354 
restriction in obese subjects with either a low-fat or low-carbohydrate diet on metabolic function 355 
is a continuum, with differential effects on specific organ systems.  Brief (48 h) CR and minimal 356 
weight loss (~2% of initial body weight) primarily affects the liver, manifested by a decrease in 357 
IHTG content, an increase in hepatic insulin sensitivity, and a decrease in endogenous glucose 358 
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production, whereas longer (~11 wks) CR and moderate weight loss (~7% of initial body weight) 359 
primarily affects skeletal muscle, manifested by an increase in muscle insulin-mediated glucose 360 
uptake and enhanced cellular insulin signaling.  These findings help explain the rapid 361 
improvement in glucose homeostasis observed after low-calorie diet therapy and bariatric 362 
surgery.363 
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Table 1.  Baseline body composition and metabolic characteristics of the study subjects 503 
 High-carbohydrate 
diet group (n=11) 
Low-carbohydrate 
diet group (n=11) 
All subjects 
(n=22) 
Age (yrs) 45.4  4.0 41.8  3.1 43.6  2.5 
Body weight (kg) 101.0  4.1 101.9  4.0 101.5  2.8 
BMI (kg/m2) 36.9  1.2 36.1  1.0 36.5  0.8 
Fat-free mass (kg) 57.2  3.1 57.9  3.2 57.6  2.2 
Fat mass (kg) 41.7  2.4 42.1  1.7 41.9  1.4 
Fat mass (% body weight) 42.3  1.9 42.3  1.4 42.3  1.1 
Total abdominal fat volume (cm3) 5625  233 5753  321 5686  191 
Subcutaneous abdominal fat volume cm3) 4010  243 4208  385 4105  219 
Intra-abdominal fat volume (cm3) 1556  234 1544  221 1550  158 
Intrahepatic triglyceride content (%) 11.2  2.9 12.4  2.9 11.8  2.0 
Plasma glucose (mg/dL) 96.8  2.7 101.5  4.5 99.1  2.6 
Plasma insulin (µU/mL) 15.5  2.8 18.7  2.4 17.1  1.8 
Plasma triglyceride (mg/dL) 138.9  17 147.7  21.0 143.5  13 
HDL-cholesterol (mg/dL) 45.2  2.7 44.1  3.7 44.6  2.2 
LDL-cholesterol (mg/dL) 93.3  5.5 96.7  7.3 95.0  4.5 
 504 
Values are means  SEM 505 
506 
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Table 2. Percent change from baseline in body weight and metabolic variables after 48 h and 507 
11 wks (7% weight loss) of calorie restriction (CR) in subjects consuming a high carbohydrate 508 
(HC) or low-carbohydrate (LC) diet. 509 
 Percent change after 48 h CR  Percent change after ~11 weeks CR  
 HC LC HC LC 
 
Body weight -1.6  0.2** -2.2  -0.2** -7.3  0.6** -7.6  0.5** 
Plasma glucose  
-2.6  2.3 -9.8  2.4*, # -6.2  1.6* -8.9  3.0* 
Plasma insulin  
-22.0  5.1* -33.9  6.4** -22.0  5.7* -38.4  5.2**, # 
C-Peptide   
-14.4  3.5* 
 
-26.3  4.5** 
 
-12.0  3.1* 
 
-25.3  3.6** 
Free fatty acids  
13.9  6.2* 
 
32.1  8.0* 
 
-1.5  9.9 
 
-1.5  7.5 
HOMA-IR 
-23.8  5.9* -40.3  6.1**, # -27.1  5.1** -44.0  4.7**, # 
Values are means  SEM.   510 
Value significantly different from baseline value: * p<0.05, ** P<0.001.   511 
Value significantly different from value in HC group, # P<0.05.  512 
HOMA-IR: Homeostasis model assessment of insulin resistance 513 
 514 
 515 
516 
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Figure legends 517 
 518 
Figure 1.  Changes in body composition and intrahepatic triglyceride (IHTG) content after 48 h 519 
(2% weight loss) and ~11 weeks (7% weight loss) of calorie restriction in obese subjects 520 
consuming either a high-carbohydrate or low-carbohydrate 1000 kcal/d deficit diet.  Values are 521 
means  SEM.  Value significantly different from baseline value; *P<0.05, **P<0.001; #Value 522 
significantly different from corresponding high-carbohydrate diet group, P<0.05. FM=Fat Mass, 523 
FFM= Fat-free Mass 524 
 525 
Figure 2.  Relative changes in basal glucose Rate of appearance (Ra) in plasma after 48 h of 526 
calorie restriction and 7% weight loss.  Values are means  SEM. *Value significantly different 527 
from baseline value; P<0.001.  # Value significantly different from value in AC group; P<0.001. 528 
 529 
Figure 3. Hepatic insulin sensitivity index (HISI) (top panel) in subjects consuming ether a high-530 
carbohydrate or low-carbohydrate diet and changes in insulin mediated glucose uptake, an 531 
index of skeletal muscle insulin sensitivity, in both groups combined (bottom panel) after 48 h 532 
and ~11 wks (7% weight loss) of calorie restriction.  Value significantly different from baseline 533 
value: * P<0.05, ** P<0.001.   Value significantly different from value in HC group, # P<0.05.  534 
 535 
Figure 4. Changes in phosphoTyr183 JNK, phosphoTyr IRS, and phosphoSer473 Akt/PKB 536 
protein levels in vastus lateralis muscle biopsies obtained after 30 min of insulin infusion during 537 
a euglycemic-hyperinsulinenmic clamp procedure after 48 h and ~11 wks (7% weight loss) of 538 
calorie restriction. Values are corrected for total JNK, IRS1, and Akt/PKB protein content and 539 
normalized (=0) to values from baseline samples (day 0).  Values are means SEM. Value 540 
significantly different from corresponding baseline value, *p<0.05.  541 
542 
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